Pasar al contenido principal

FUNCIONALIDAD MITOCONDRIAL Y ESTRES OXIDATIVO EN UN ESTUDIO FASE II PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON CORTICOIDES EN HEPATOTOXICIDAD

PID2022-140169OB-C21

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD (FIMABIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RIUMA. Repositorio Institucional de la Universidad de Málaga
Publicación Artículo científico (JournalArticle)

Systematic review on genetic polymorphisms associated with idiosyncratic drug-induced liver injury (iDILI): iDILInet as an interactive visualization tool

  • Matilla-Cabello, Gonzalo
  • Remesal-Doblado, Ángela
  • Celebi-Cinar, Muzzez
  • Bodoque-García, Ana
  • Betul Metin, Fatma
  • Rezaei, Aida
  • Aftab, Moiz
  • De los Santos-Fernández, Romina
  • Segovia-Zafra, Antonio
  • Álvarez-Álvarez, Ismael
  • Andrade-Bellido, Raúl Jesús
  • Cakan-Akdogan, Gulcin
  • Lucena-González, María Isabel
  • Konu, Ozlen
  • Villanueva-Paz, Marina
Idiosyncratic drug-induced liver injury (iDILI) is a rare, dose-independent and unpredictable adverse reaction occurring at therapeutic drug exposure, and it presents a significant challenge for drug development and patient safety. Despite extensive research, genetic susceptibility to iDILI remains poorly understood. We conducted a comprehensive systematic study of 139 human genetic studies to identify and characterize genetic polymorphisms associated with increased risk or protection against iDILI. Our study included candidate gene studies and genome-wide association studies (GWAS), encompassing 83 risk and 25 protective genes, with NAT2, HLA-B, and SLCO1B1 among the most frequently reported. We performed functional enrichment analyses using KEGG and Gene Ontology, revealing key biological pathways related to immune response, xenobiotic metabolism, and bile secretion. To enhance data accessibility and interpretation, we developed iDILInet, a publicly available web application that enables interactive exploration and network-based visualization of iDILI-associated gene-variant-drug relationships, enriched with liver-specific expression data from the Human Protein Atlas (HPA). Our work provides a novel integrative resource that supports ongoing efforts in precision medicine and pharmacogenomics and represents a significant advancement in implementing living systematic reviews in toxicogenomics., Consejería de Salud de Andalucía, Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Agencia Española del Medicamento y Productos Sanitarios, Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación, Universidad de Málaga
RIUMA. Repositorio Institucional de la Universidad de Málaga
Publicación Artículo científico (JournalArticle)

Epigenetic modifications in drug-induced liver injury: A systematic review

  • de los Santos-Fernández, Romina Lorena
  • Segovia-Zafra, Antonio
  • Paz-López, Guillermo
  • Matilla-Cabello, Gonzalo
  • Niu, Hao
  • Álvarez-Álvarez, Ismael
  • Stephens, Camilla
  • Lucena-González, María Isabel
  • Andrade-Bellido, Raúl Jesús
  • Medina-Cáliz, Inmaculada
Genetic susceptibility has been identified in idiosyncratic drug-induced liver injury, a potentially severe adverse reaction towards drugs, herbal products and dietary supplements. However, its occurrence cannot be fully explained by the presence of genetic variants in specific genes, suggesting that other factors are involved. Druginduced liver injury epigenetic signatures could help explain genetic regulatory mechanisms behind this disease and might provide disease biomarkers. This systematic review aims to analyse all available information on epigenetic risk association studies in drug-induced liver injury. The main inclusion criterion was population studies on idiosyncratic drug-induced liver injury with significant risk association analysis between drug-induced liver injury and an epigenetic regulation mechanism. Out of the 7 included articles, 6 focused on DNA methylation and 1 on long noncoding RNA. All of the studies were on antituberculosis drug-induced liver injury and came from Asia. CpG site methylation in the CYP2D6 (odds ratio: 9.19, 95% confidence interval: 3.26–25.89, P < .001) and NAT2 (odds ratio: 8.37, 95% confidence interval: 2.39–29.32, P = .001) promoters conferred the highest risk. Hypomethylation of LINE-1 and Alu transposable elements has potential as antituberculosis drug-induced liver injury biomarkers, showing an area under the curve value of 0.94. To conclude, the studies mainly focused on DNA methylation modifications associated with antituberculosis drug-induced liver injury, with all of them coming from Asia, where tuberculosis is a public health burden. Despite the lack of knowledge in this area, the evidence has shown that DNA methylation alterations in antituberculosis drug-induced liver injury could have potential as a new diagnostic and therapeutic target., Instituto de Salud Carlos III, Agencia Estatal de Investigación, CIBER, European Comission
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

  • Lucena, M. Isabel
  • Villanueva-Paz, M.
  • Álvarez-Álvarez, I.
  • Aithal, G. P.
  • Björnsson, E. S.
  • Cakan-Akdogan, G.
  • Cubero, Francisco Javier
  • Esteves, F.
  • Falcón-Pérez, Juan M.
  • Fromenty, B.
  • García-Ruiz, Carmen
  • Grove, J. I.
  • Konu, O.
  • Kranendonk, M.
  • Kullak-Ublick, G. A.
  • Miranda, Joana
  • Remesal-Doblado, A.
  • Sancho-Bru, P.
  • Nelson, L.
  • Andrade, Raúl J.
  • Daly, A. K.
  • Fernández-Checa, José C.
In the current article the aims for a constructive way forward in Drug-Induced Liver Injury (DILI) are to highlight the most important priorities in research and clinical science, therefore supporting a more informed, focused, and better funded future for European DILI research. This Roadmap aims to identify key challenges, define a shared vision across all stakeholders for the opportunities to overcome these challenges and propose a high-quality research program to achieve progress on the prediction, prevention, diagnosis and management of this condition and impact on healthcare practice in the field of DILI. This will involve 1. Creation of a database encompassing optimised case report form for prospectively identified DILI cases with well-characterised controls with competing diagnoses, biological samples, and imaging data; 2. Establishing of preclinical models to improve the assessment and prediction of hepatotoxicity in humans to guide future drug safety testing; 3. Emphasis on implementation science and 4. Enhanced collaboration between drug-developers, clinicians and regulatory scientists. This proposed operational framework will advance DILI research and may bring together basic, applied, translational and clinical research in DILI., The present study has been supported by grants from Instituto de Salud Carlos III (ISCIII) (contract numbers: PID2022–140169OB-C21; PI21/01248; PI19/00883) and from Consejería de Salud de Andalucía (contract number: PEMP-0127–2020, Spain), cofounded by the European Union. This research was funded by HORIZON-HLTH-2022-STAYHLTH-02, grant number 101095679. Funded by the European Union. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. MK was partially supported by Grant UID/BIM/0009/2020 of the Portuguese Fundação para a Ciência e a Tecnologia (FCT). MVP and IAA hold Sara Borrell research contracts from ISCIII (CD21/00198 and CD20/00083, respectively). This research was supported by CIBERehd – Consorcio Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – European Regional Development Fund. JIG and GPA are supported by NIHR Nottingham Biomedical Research Centre [NIHR203310]. The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. This publication is based upon work from COST Action “CA17112—Prospective European Drug-Induced Liver Injury Network” supported by COST (European Cooperation in Science and Technology); www.cost.eu., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Expression of SREBF2 and HMGCR discriminates the viability of steatotic grafts for human liver transplantation

  • Baulies, Anna
  • Torres, Sandra
  • Fucho, Raquel
  • Nuñez, Susana
  • Torres, Ferrán
  • Ferrer, Joana
  • Díaz, Alba
  • Rico, Naira
  • García-Valdecasas, Juan Carlos
  • Fuster, Josep
  • Adalia, Ramón
  • Paredes, David
  • Rimola, Antoni
  • Fernández-Checa, José C.
  • García-Ruiz, Carmen
We acknowledge the support from the grants Fundación Mutua Madrileña; grants PID2022-142956OB-100, PID2022-140169OB-C22 and PID2023-148803OB-100 from Plan Nacional de I + D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; as well as support from National Cancer Institute PO1 CA281819-01A1 from the NIH; AGAUR of the Generalitat de Catalunya SGR-2021-00491; ST holds a Ramón y Cajal fellowship (RYC2023-042649-I), and has received research support from the CIBEREHD intramural project 2023 (EHD25PI01). In addition, this project has received funding from the European Horizon's research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679., Peer reviewed